Print

Active Biotech AB Interim report January - June 2012

2012-08-10

  • Laquinimod- application submitted for regulatory approval in the EU resulting inmilestone payment of USD 5 M
    duringthirdquarter 2012
    - a Phase III study will be initiated in the US
  • TASQ- milestone payment of EUR 10 M received from Ipsen inconnection with meeting patient enrolment target
    forPhase III study
    - overall survival data from Phase II study presented
  • ANYARA- Phase III trial continuing according to plan
  • 57-57- a clinical trial in systemic sclerosis/scleroderma in progress
  • ISI- project proceeding as planned
  • The organization has been adapted to the company's new direction
  • Net sales: SEK 96.6 M (228.8)
  • Operating loss: SEK 120.6 M (profit: 70.6)
  • Loss after tax: SEK 123.5 M (profit: 77.7)
  • Loss per share for the period: SEK 1.79 (earnings: 1.14)

For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95

Hans Kolam
CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00


This report is also available at www.activebiotech.com Fax: +46 (0)46 19 11 00


pdfActive Biotech AB Interim report Jan - June 2012



Back